172 related articles for article (PubMed ID: 37695315)
21. Oxidative stress induced by inactivation of TP53INP1 cooperates with KrasG12D to initiate and promote pancreatic carcinogenesis in the murine pancreas.
Al Saati T; Clerc P; Hanoun N; Peuget S; Lulka H; Gigoux V; Capilla F; Béluchon B; Couvelard A; Selves J; Buscail L; Carrier A; Dusetti N; Dufresne M
Am J Pathol; 2013 Jun; 182(6):1996-2004. PubMed ID: 23578383
[TBL] [Abstract][Full Text] [Related]
22. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.
Diersch S; Wirth M; Schneeweis C; Jörs S; Geisler F; Siveke JT; Rad R; Schmid RM; Saur D; Rustgi AK; Reichert M; Schneider G
Oncogene; 2016 Jul; 35(29):3880-6. PubMed ID: 26592448
[TBL] [Abstract][Full Text] [Related]
23. SIRT2 deletion enhances KRAS-induced tumorigenesis in vivo by regulating K147 acetylation status.
Song HY; Biancucci M; Kang HJ; O'Callaghan C; Park SH; Principe DR; Jiang H; Yan Y; Satchell KF; Raparia K; Gius D; Vassilopoulos A
Oncotarget; 2016 Dec; 7(49):80336-80349. PubMed ID: 27637077
[TBL] [Abstract][Full Text] [Related]
24. Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis.
Sun Q; Guo Y; Hu W; Zhang M; Wang S; Lei Y; Meng H; Li N; Xu P; Li Z; Lin H; Huang F; Qiu Z
Drug Metab Dispos; 2023 Dec; 51(12):1628-1641. PubMed ID: 37684055
[TBL] [Abstract][Full Text] [Related]
25. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
Weyandt JD; Lampson BL; Tang S; Mastrodomenico M; Cardona DM; Counter CM
PLoS One; 2015; 10(10):e0140253. PubMed ID: 26452271
[TBL] [Abstract][Full Text] [Related]
26. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
[TBL] [Abstract][Full Text] [Related]
27. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.
Gruber R; Panayiotou R; Nye E; Spencer-Dene B; Stamp G; Behrens A
Gastroenterology; 2016 Sep; 151(3):526-39. PubMed ID: 27215660
[TBL] [Abstract][Full Text] [Related]
28. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
29. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
[TBL] [Abstract][Full Text] [Related]
30. Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Li H; Yang AL; Chung YT; Zhang W; Liao J; Yang GY
Carcinogenesis; 2013 Sep; 34(9):2090-8. PubMed ID: 23689354
[TBL] [Abstract][Full Text] [Related]
31. A high-fat diet activates oncogenic Kras and COX2 to induce development of pancreatic ductal adenocarcinoma in mice.
Philip B; Roland CL; Daniluk J; Liu Y; Chatterjee D; Gomez SB; Ji B; Huang H; Wang H; Fleming JB; Logsdon CD; Cruz-Monserrate Z
Gastroenterology; 2013 Dec; 145(6):1449-58. PubMed ID: 23958541
[TBL] [Abstract][Full Text] [Related]
32. Differential Contribution of Pancreatic Fibroblast Subsets to the Pancreatic Cancer Stroma.
Garcia PE; Adoumie M; Kim EC; Zhang Y; Scales MK; El-Tawil YS; Shaikh AZ; Wen HJ; Bednar F; Allen BL; Wellik DM; Crawford HC; Pasca di Magliano M
Cell Mol Gastroenterol Hepatol; 2020; 10(3):581-599. PubMed ID: 32454112
[TBL] [Abstract][Full Text] [Related]
33. KrasG12D-LOH promotes malignant biological behavior and energy metabolism of pancreatic ductal adenocarcinoma cells through the mTOR signaling pathway.
Shen X; Chang LG; Hu MY; Yan D; Zhou LN; Ma Y; Ling SK; Fu YQ; Zhang SY; Kong B; Huang PL
Neoplasma; 2018; 65(1):81-88. PubMed ID: 29322792
[TBL] [Abstract][Full Text] [Related]
34. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
Wu CY; Carpenter ES; Takeuchi KK; Halbrook CJ; Peverley LV; Bien H; Hall JC; DelGiorno KE; Pal D; Song Y; Shi C; Lin RZ; Crawford HC
Gastroenterology; 2014 Dec; 147(6):1405-16.e7. PubMed ID: 25311989
[TBL] [Abstract][Full Text] [Related]
35. An oncogenic KRAS transcription program activates the RHOGEF ARHGEF2 to mediate transformed phenotypes in pancreatic cancer.
Kent OA; Sandí MJ; Burston HE; Brown KR; Rottapel R
Oncotarget; 2017 Jan; 8(3):4484-4500. PubMed ID: 27835861
[TBL] [Abstract][Full Text] [Related]
36. KRAS mutant-driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer.
Luo Y; Li Z; Kong Y; He W; Zheng H; An M; Lin Y; Zhang D; Yang J; Zhao Y; Chen C; Chen R
J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35579947
[TBL] [Abstract][Full Text] [Related]
37. p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis.
Le Roux Ö; Everitt JI; Counter CM
PLoS One; 2024; 19(3):e0292189. PubMed ID: 38547169
[TBL] [Abstract][Full Text] [Related]
38. Cytokine CCL9 Mediates Oncogenic KRAS-Induced Pancreatic Acinar-to-Ductal Metaplasia by Promoting Reactive Oxygen Species and Metalloproteinases.
Liou GY; Byrd CJ; Storz P; Messex JK
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731942
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of the mitochondrial citrate carrier, Slc25a1, reverts steatosis, glucose intolerance, and inflammation in preclinical models of NAFLD/NASH.
Tan M; Mosaoa R; Graham GT; Kasprzyk-Pawelec A; Gadre S; Parasido E; Catalina-Rodriguez O; Foley P; Giaccone G; Cheema A; Kallakury B; Albanese C; Yi C; Avantaggiati ML
Cell Death Differ; 2020 Jul; 27(7):2143-2157. PubMed ID: 31959914
[TBL] [Abstract][Full Text] [Related]
40. Targeting metabolic reprogramming in KRAS-driven cancers.
Kawada K; Toda K; Sakai Y
Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
